Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sulzinc is a pharmaceutical formulation of zinc sulfate developed and marketed by Humax Pharmaceutical. It is primarily indicated as a nutritional supplement for the treatment and prevention of zinc deficiency and as an adjunct therapy in the management of acute and persistent diarrhea in pediatric populations. Zinc is an essential trace element that serves as a cofactor for more than 300 enzymes involved in diverse biological processes, including DNA synthesis, protein production, cell division, and immune system regulation. In the gastrointestinal tract, zinc supplementation helps restore mucosal integrity and intestinal enzyme activity, thereby reducing the duration and severity of diarrheal episodes. The product is typically available in oral drop and syrup formulations to facilitate administration in children.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on zinc sulfate.